Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development

Pharmaceutical Research

Volumn 32, Issue 11, 2015, Pages 3508-3525

  Singh, Aman P ^a   Shin, Young G ^b   Shah, Dhaval K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Chungnam National University   (South Korea)

Author keywords

antibody drug conjugate (ADC); model based drug development; modeling and simulation; pharmacodynamics; pharmacokinetics; PK PD; preclinical to clinical translation

Indexed keywords

ANTIBODY CONJUGATE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; CELL CYCLE M PHASE; CELL DIVISION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; IMMUNOCONJUGATES; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84943586922     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1626-1     Document Type: Review

References (44)

1. Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1-27.
2. Minich SS. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother. 2012;46(3):377-83.
3. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep. 2013;30(5):625-39.
4. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329-32.
5. Shah DK, Barletta F, Betts A, Hansel S. Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective. Bioanalysis. 2013;5(9):989-92.
6. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther. 2013;93(6):502-14.
7. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643-59.
8. Jackson D, Atkinson J, Guevara CI, Zhang C, Kery V, Moon SJ, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE. 2014;9(1):e83865.
9. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(3):888-97.
10. Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn. 2013;40(5):557-71.
11. Hamed SS, Roth CM. Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves. J Pharmacokinet Pharmacodyn. 2011;38(3):385-403.
12. Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751-61.
13. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013;5(9):997-1006.
14. Wagner-Rousset E, Janin-Bussat MC, Colas O, Excoffier M, Ayoub D, Haeuw JF, et al. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. mAbs. 2014;6(1):273-85.
15. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014.
16. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(20):7063-70.
17. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34-45.
18. Sukumaran S, Gadkar K, Zhang C, Bhakta S, Xu K, Raab H, et al. Mechanism-based pharmacokinetic/pharmacodynamics model for THIOMAB drug conjugates. Annual conference of American Association of Pharmaceutical Sciences (AAPS). Texas; 2013. Poster # T3237.
19. Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, et al. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J. 2014;16(3):452-63.
20. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861-71.
21. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57-61.
22. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med Off Publ, Soc Nucl Med. 2007;48(6):995-9.
23. Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PLoS ONE. 2011;6(9):e24696.
24. Shah DK, Balthasar JP. Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn. 2011;38(1):121-42.
25. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67-86.
26. Shah DK, Balthasar JP. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J Pharmacokinet Pharmacodyn. 2014;41(1):55-69.
27. Shah DK, Balthasar JP. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. Int J Pharm. 2014;465(1-2):228-38.
28. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687-709.
29. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs. 2013;5(2):297-305.
30. Zhao B, Zheng S, Alley SC. Physiologically-based pharmacokinetic modeling of an anti-CD70 auristatin antibody-drug conjugate in tumor-bearing mice. American Conference on Pharmacometrics (ACoP). San Diego; 2011.
31. Chen Y, Samineni D, Mukadam S, Wong H, Shen BQ, Lu D, et al. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. Clin Pharmacokinet. 2014.
32. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64(3):1094-101.
33. Lobo ED, Balthasar JP. Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPPS Pharmsci. 2002;4(4):E42.
34. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010;37(3):221-42.
35. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Onco Off J Am Soc Clin Oncol. 2002;20(24):4713-21.
36. Tatipalli M, Derendorf H. Semi-physiological population PK/PD model of ADC neutropenia. M.S. Thesis. Pharmaceutical Sciences. Gainesville: University of Florida; 2012.
37. Gupta M, Lorusso PM, Wang B, Yi JH, Burris 3rd HA, Beeram M, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52(5):691-703.
38. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012;70(4):591-601.
39. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52(8):657-72.
40. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012;92(4):520-7.
41. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32.
42. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2014;41(1):35-47.
43. Luu K, Vandendries E, Volkert A, Ogura M, Goy G, Boni J. Antitumor response to inotuzumab ozogamicin (INO) in patients with refractory or relapsed indolent B-cell non-Hodgkin's lymphomas (NHL): pharmacokinetic-pharmacodynamic (PK-PD) modeling and interim results from a phase II study AACR 103rd Annual Meeting Chicago; 2012. Poster # 7114.
44. Mugundu G, Vandendries E, Boni J. Use of pharmacokinetic-pharmacodynamic modeling to characterize platelet response following inotuzumab ozogamicin treatment in patients with follicular or diffuse large B-cell non-Hodgkin's lymphoma AACR 103rd Annual Meeting Chicago; 2012. Poster # 3776.